ATA10002000A - Antigene zusammensetzung - Google Patents

Antigene zusammensetzung

Info

Publication number
ATA10002000A
ATA10002000A AT0100000A AT10002000A ATA10002000A AT A10002000 A ATA10002000 A AT A10002000A AT 0100000 A AT0100000 A AT 0100000A AT 10002000 A AT10002000 A AT 10002000A AT A10002000 A ATA10002000 A AT A10002000A
Authority
AT
Austria
Prior art keywords
composition
antique
inosin
cytosin
vaccine
Prior art date
Application number
AT0100000A
Other languages
English (en)
Other versions
AT410173B (de
Original Assignee
Cistem Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT0100000A priority Critical patent/AT410173B/de
Application filed by Cistem Biotechnologies Gmbh filed Critical Cistem Biotechnologies Gmbh
Priority to TR200302015T priority patent/TR200302015T4/xx
Priority to CZ2002-4168A priority patent/CZ304195B6/cs
Priority to AU2001262345A priority patent/AU2001262345A1/en
Priority to PL358982A priority patent/PL211036B1/pl
Priority to RU2007103151A priority patent/RU2413520C2/ru
Priority to AU2001281812A priority patent/AU2001281812B2/en
Priority to EP01936440A priority patent/EP1286695B1/de
Priority to CA2411575A priority patent/CA2411575C/en
Priority to ES01960277T priority patent/ES2206424T3/es
Priority to IL15295901A priority patent/IL152959A0/xx
Priority to HK03109011.3A priority patent/HK1056678B/xx
Priority to US10/297,555 priority patent/US8568742B2/en
Priority to MXPA02012010A priority patent/MXPA02012010A/es
Priority to BRPI0111639A priority patent/BRPI0111639B8/pt
Priority to SI200130047T priority patent/SI1296713T1/xx
Priority to AU8181201A priority patent/AU8181201A/xx
Priority to EP20010960277 priority patent/EP1296713B1/de
Priority to AT01936440T priority patent/ATE290880T1/de
Priority to PCT/EP2001/006437 priority patent/WO2001093903A1/en
Priority to DE2001600814 priority patent/DE60100814T2/de
Priority to PT01960277T priority patent/PT1296713E/pt
Priority to KR20027016711A priority patent/KR100799788B1/ko
Priority to DK01960277T priority patent/DK1296713T3/da
Priority to CNB018107974A priority patent/CN1309418C/zh
Priority to RU2003100409A priority patent/RU2293573C2/ru
Priority to DE60109443T priority patent/DE60109443T2/de
Priority to SK1815-2002A priority patent/SK287689B6/sk
Priority to AT01960277T priority patent/ATE249839T1/de
Priority to HU0301229A priority patent/HU228264B1/hu
Priority to PCT/EP2001/006433 priority patent/WO2001093905A1/en
Priority to JP2002501476A priority patent/JP5271471B2/ja
Priority to US10/297,497 priority patent/US7148191B2/en
Publication of ATA10002000A publication Critical patent/ATA10002000A/de
Priority to IS6627A priority patent/IS1993B/is
Priority to IL152959A priority patent/IL152959A/en
Priority to ZA200209479A priority patent/ZA200209479B/en
Priority to NO20025835A priority patent/NO329492B1/no
Application granted granted Critical
Publication of AT410173B publication Critical patent/AT410173B/de
Priority to US11/609,777 priority patent/US20070218073A1/en
Priority to JP2013002571A priority patent/JP5908851B2/ja
Priority to US13/786,815 priority patent/US8945591B2/en
Priority to US14/585,740 priority patent/US9492537B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT0100000A 2000-06-08 2000-06-08 Antigene zusammensetzung AT410173B (de)

Priority Applications (41)

Application Number Priority Date Filing Date Title
AT0100000A AT410173B (de) 2000-06-08 2000-06-08 Antigene zusammensetzung
PT01960277T PT1296713E (pt) 2000-06-08 2001-06-07 Oligodesoxinucleotidos imunoestimuladores
AU2001262345A AU2001262345A1 (en) 2000-06-08 2001-06-07 Antigenic composition comprising a polycationic peptide and inosine and cytosine
PL358982A PL211036B1 (pl) 2000-06-08 2001-06-07 Zastosowanie cząsteczki immunostymulującego kwasu oligodezoksynukleinowego (ODN) i zawierająca ją kompozycja
RU2007103151A RU2413520C2 (ru) 2000-06-08 2001-06-07 Вакцинная композиция, содержащая иммуностимулирующие олигодезоксинуклеотиды
AU2001281812A AU2001281812B2 (en) 2000-06-08 2001-06-07 Immunostimulatory oligodeoxynucleotides
EP01936440A EP1286695B1 (de) 2000-06-08 2001-06-07 Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält
CA2411575A CA2411575C (en) 2000-06-08 2001-06-07 Immunostimulatory oligodeoxynucleotides
ES01960277T ES2206424T3 (es) 2000-06-08 2001-06-07 Oligodesoxinucleotidos inmunoestimulantes.
IL15295901A IL152959A0 (en) 2000-06-08 2001-06-07 Immunostimulatory oligodeoxynucleotides
HK03109011.3A HK1056678B (zh) 2000-06-08 2001-06-07 免疫刺激性寡脱氧核苷酸
US10/297,555 US8568742B2 (en) 2000-06-08 2001-06-07 Methods and compositions involving immunostimulatory oligodeoxynucleotides
MXPA02012010A MXPA02012010A (es) 2000-06-08 2001-06-07 Oligodesoxinucleotidos inmunoestimulantes.
BRPI0111639A BRPI0111639B8 (pt) 2000-06-08 2001-06-07 uso de uma molécula de ácido oligodeoxinucléico imunoestimulatório e composição farmacêutica.
SI200130047T SI1296713T1 (en) 2000-06-08 2001-06-07 Immunostimulatory oligodeoxynucleotides
AU8181201A AU8181201A (en) 2000-06-08 2001-06-07 Immunostimulatory oligodeoxynucleotides
EP20010960277 EP1296713B1 (de) 2000-06-08 2001-06-07 Immunstimulierende oligodeoxynukleotide
DK01960277T DK1296713T3 (da) 2000-06-08 2001-06-07 Immunstimulerende oligodeoxynukleotider
PCT/EP2001/006437 WO2001093903A1 (en) 2000-06-08 2001-06-07 Antigenic composition comprising a polycationic peptide and inosine and cytosine
DE2001600814 DE60100814T2 (de) 2000-06-08 2001-06-07 Immunstimulierende oligodeoxynukleotide
TR200302015T TR200302015T4 (tr) 2000-06-08 2001-06-07 İmüno-uyarıcı oligodeoksinükleotitler
AT01936440T ATE290880T1 (de) 2000-06-08 2001-06-07 Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält
CZ2002-4168A CZ304195B6 (cs) 2000-06-08 2001-06-07 Imunostimulační farmaceutický přípravek
CNB018107974A CN1309418C (zh) 2000-06-08 2001-06-07 免疫刺激性寡脱氧核苷酸
RU2003100409A RU2293573C2 (ru) 2000-06-08 2001-06-07 Иммуностимулирующие олигодезоксинуклеотиды
DE60109443T DE60109443T2 (de) 2000-06-08 2001-06-07 Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält
SK1815-2002A SK287689B6 (sk) 2000-06-08 2001-06-07 Použitie molekuly oligodeoxynukleovej kyseliny na výrobu imunostimulačnej farmaceutickej kompozície a farmaceutický prípravok
AT01960277T ATE249839T1 (de) 2000-06-08 2001-06-07 Immunstimulierende oligodeoxynukleotide
HU0301229A HU228264B1 (en) 2000-06-08 2001-06-07 Immunostimulatory oligodeoxynucleotides
PCT/EP2001/006433 WO2001093905A1 (en) 2000-06-08 2001-06-07 Immunostimulatory oligodeoxynucleotides
JP2002501476A JP5271471B2 (ja) 2000-06-08 2001-06-07 免疫促進性オリゴデオキシヌクレオチド
US10/297,497 US7148191B2 (en) 2000-06-08 2001-06-07 Antigenic composition
KR20027016711A KR100799788B1 (ko) 2000-06-08 2001-06-07 면역촉진성 올리고디옥시뉴클레오티드
IS6627A IS1993B (is) 2000-06-08 2002-11-18 Ónæmisörvandi fádeoxýkirni
IL152959A IL152959A (en) 2000-06-08 2002-11-20 Use of immunostimulatory oligodeoxynucleotides for the preparation of immunostimulatory pharmaceutical compositions
ZA200209479A ZA200209479B (en) 2000-06-08 2002-11-21 Immunostimulatory oligodeoxynucleotides.
NO20025835A NO329492B1 (no) 2000-06-08 2002-12-04 Anvendelse av immunstimulerende oligodeoksynukleinsyremolekyler for fremstilling av immunstimulerende, farmasoytiske sammensetninger og farmasoytiske sammensetninger som inneholder de samme.
US11/609,777 US20070218073A1 (en) 2000-06-08 2006-12-12 Antigenic composition
JP2013002571A JP5908851B2 (ja) 2000-06-08 2013-01-10 免疫促進性オリゴデオキシヌクレオチド
US13/786,815 US8945591B2 (en) 2000-06-08 2013-03-06 Methods and compositions involving immunostimulatory oligodeoxynucleotides
US14/585,740 US9492537B2 (en) 2000-06-08 2014-12-30 Methods and compositions involving immunostimulatory oligodeoxynucleotides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0100000A AT410173B (de) 2000-06-08 2000-06-08 Antigene zusammensetzung

Publications (2)

Publication Number Publication Date
ATA10002000A true ATA10002000A (de) 2002-07-15
AT410173B AT410173B (de) 2003-02-25

Family

ID=3683921

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0100000A AT410173B (de) 2000-06-08 2000-06-08 Antigene zusammensetzung
AT01936440T ATE290880T1 (de) 2000-06-08 2001-06-07 Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01936440T ATE290880T1 (de) 2000-06-08 2001-06-07 Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält

Country Status (7)

Country Link
US (2) US7148191B2 (de)
EP (1) EP1286695B1 (de)
AT (2) AT410173B (de)
AU (1) AU2001262345A1 (de)
DE (1) DE60109443T2 (de)
WO (1) WO2001093903A1 (de)
ZA (1) ZA200209479B (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046224A2 (en) * 1999-12-22 2001-06-28 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
WO2001093905A1 (en) 2000-06-08 2001-12-13 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Immunostimulatory oligodeoxynucleotides
AT410173B (de) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
ES2307568T3 (es) * 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
CA2433561C (en) * 2001-01-03 2014-04-01 Willmar Poultry Company, Inc. Compositions including gram negative siderophore receptor proteins and methods of use
WO2002053185A2 (en) * 2001-01-05 2002-07-11 Intercell Ag Anti-inflammatory use of polycationic compounds
EP1347775B1 (de) 2001-01-05 2016-11-30 Valneva Austria GmbH Gebrauch von polykationischen substanzen als adjuvantien für impfstoffe
CA2452909A1 (en) * 2001-12-07 2003-06-13 Intercell Ag Immunostimulatory oligodeoxynucleotides
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
CN1659436A (zh) * 2002-02-28 2005-08-24 英特塞尔股份公司 分离配体的方法
WO2003090685A2 (en) * 2002-04-24 2003-11-06 The Regents Of The University Of California Methods for stimulating tlr/irf3 pathways for inducing anti-microbial, anti-inflammatory and anticancer responses
WO2005102278A1 (en) * 2002-07-03 2005-11-03 Oncovir, Inc. Method for preparation of poly-iclc and uses thereof
CA2484941A1 (en) 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
WO2004024182A2 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
EP2314603A3 (de) 2002-10-15 2011-05-18 Intercell AG Bindungdsfaktoren von Gruppe B-Streptococcus, dafür kodierende Nukleinsäuren und Verwendungen davon
AU2003297317A1 (en) * 2002-12-13 2004-07-09 Case Western Reserve University Defensin-inducing peptides from fusobacterium
EP1601770B1 (de) 2003-03-04 2009-09-02 Intercell AG Streptococcus pyogenes antigene
CN100355453C (zh) * 2003-03-24 2007-12-19 英特塞尔股份公司 改进的疫苗
ES2562456T3 (es) * 2003-03-24 2016-03-04 Valneva Austria Gmbh Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes
EP1608756B1 (de) 2003-03-31 2009-11-18 Intercell AG Staphylococcus epidermidis antigene
EP2333114A1 (de) 2003-04-15 2011-06-15 Intercell AG S. pneumoniae Antigene
EP1620460A2 (de) 2003-05-07 2006-02-01 Intercell AG Streptococcus agalactiae-antigene i + ii
CN102304527A (zh) 2003-05-30 2012-01-04 英特塞尔股份公司 肠球菌抗原
ES2395022T3 (es) * 2003-09-19 2013-02-07 Epitopix, Llc Polipéptidos de Campylobacter y sus métodos de uso
CA2583026A1 (en) * 2004-10-29 2006-05-04 Intercell Ag Hcv vaccines for chronic hcv patients
EP1853306B1 (de) 2005-02-14 2016-06-15 Epitopix, LLC Polypeptide von staphylococcus aureus und methoden zu deren verwendung
EP2040745B1 (de) 2006-06-28 2012-12-05 Statens Serum Institut Expansion des t-zell-repertoirs, um subdominante epitope durch impfung mit antigenen, die als proteinfragmente oder peptidcocktails abgegeben werden, aufzunehmen
EP2319862A1 (de) 2006-07-07 2011-05-11 Intercell AG Kleine Streptococcus-pyogenes-Antigene und Verwendung dafür
WO2008031133A2 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
EP1923069A1 (de) 2006-11-20 2008-05-21 Intercell AG Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen
US8343510B2 (en) 2007-01-12 2013-01-01 Intercell Ag Protective proteins of S. agalactiae, combinations thereof and methods of using the same
US20090041809A1 (en) * 2007-03-07 2009-02-12 Nventa Biopharmaceuticals Corporation Double-stranded locked nucleic acid compositions
EP2152731A2 (de) 2007-05-02 2010-02-17 Intercell AG Klebsiella-antigene
EP2012122A1 (de) 2007-07-06 2009-01-07 Medigene AG Strukturproteine von mutierten Parvoviren als Impfstoffe
WO2008145400A2 (en) 2007-05-31 2008-12-04 Medigene Ag Mutated structural protein of a parvovirus
AU2008265218A1 (en) 2007-06-18 2008-12-24 Intercell Ag Chlamydia antigens
JP5731198B2 (ja) 2007-09-27 2015-06-10 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用
EP2247308A4 (de) * 2008-01-10 2012-04-18 Nventa Biopharmaceuticals Corp Hilfsstoffzusammensetzungen mit poly-ic und einem kationischen polymer
CN101977927A (zh) 2008-03-17 2011-02-16 英特塞尔股份公司 针对肺炎链球菌保护的肽以及与其有关的组合物、方法和用途
CN102056622B (zh) 2008-06-05 2016-04-06 免疫疫苗技术有限公司 包含脂质体、抗原、多核苷酸和含疏水物质的连续相的载体的组合物
WO2009156960A2 (en) 2008-06-27 2009-12-30 Pfizer Inc. Novel adjuvant compositions
US20130243779A1 (en) 2009-02-05 2013-09-19 Intercell Ag Peptides protective against e. faecalis, methods and uses relating thereto
EP2405938A2 (de) 2009-02-13 2012-01-18 Intercell AG Nicht typisierbare haemophilus influenza-antigene
EP2411046B1 (de) 2009-03-23 2017-12-06 Epitopix, LLC Polypeptide und immunisierungszusammensetzungen mit gram-prositiven polypeptiden und anwendungsverfahren
EP2308896A1 (de) 2009-10-09 2011-04-13 Sanofi-aventis Polypeptides zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
WO2011042548A1 (en) 2009-10-09 2011-04-14 Sanofi-Aventis Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
EP2319871A1 (de) 2009-11-05 2011-05-11 Sanofi-aventis Polypeptide zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
SMT201700124T1 (it) 2010-09-03 2017-05-08 Valneva Austria Gmbh Polipeptide isolato delle proteine di tossina a e tossina b di c. difficile e relativi usi
AR082925A1 (es) 2010-09-08 2013-01-16 Medigene Ag Proteinas estructurales mutadas por parvovirus con epitopo de celulas b de proteccion cruzada, producto y metodos relacionados
WO2012139094A2 (en) 2011-04-08 2012-10-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of developing a vaccine using peptide-poly ic complexes
UA121200C2 (uk) 2013-09-19 2020-04-27 Зоетіс Сервісіз Ллс Ад'ювант на основі олії
EP4248992A3 (de) 2015-01-16 2023-12-27 Zoetis Services LLC Impfstoffs gegen maul- und klauenseuche
US10166280B2 (en) 2016-06-08 2019-01-01 Epitopix, Llc Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
JP2021513840A (ja) 2018-02-16 2021-06-03 ２エー ファーマ アーベー 自己免疫疾患の処置のためのパルボウイルス構造タンパク質
EP3527223A1 (de) 2018-02-16 2019-08-21 2A Pharma AB Mutiertes parvovirus-strukturprotein
PH12021552736A1 (en) 2019-05-20 2022-07-11 Valneva Se A subunit vaccine for treatment or prevention of a respiratory tract infection
WO2020240268A1 (en) 2019-05-31 2020-12-03 Universidad De Chile An immunogenic formulation that induces protection against shiga toxin-producing escherichia coli (stec)
US20230372464A1 (en) 2020-10-07 2023-11-23 Valneva Sweden Ab Cholera vaccine formulation
US20240358812A1 (en) 2021-04-09 2024-10-31 Valneva Se Human metapneumovirus combination vaccine
WO2023083964A1 (en) 2021-11-11 2023-05-19 2A Pharma Ab Parvovirus structural protein against beta- and gamma-hpv
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR6801650D0 (pt) 1968-08-20 1973-03-07 R Maes Processo para preparacao de complexos geradores de interferon
US3725545A (en) * 1971-02-03 1973-04-03 R Maes Enhancement of antibody production by nucleic acid-polycation complexes
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
EP0934330A1 (de) 1996-07-24 1999-08-11 Michelle M. Hanna Basengeschuetzte nukleotid-analoge mit geschuetzten thiolgruppen
ATE375169T1 (de) * 2000-04-14 2007-10-15 Intercell Ag Modifizierte peptide enthaltende pharmazeutische präparationen
AT410173B (de) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung

Also Published As

Publication number Publication date
WO2001093903A1 (en) 2001-12-13
ATE290880T1 (de) 2005-04-15
ZA200209479B (en) 2003-11-21
DE60109443D1 (de) 2005-04-21
AT410173B (de) 2003-02-25
DE60109443T2 (de) 2006-04-13
US7148191B2 (en) 2006-12-12
EP1286695B1 (de) 2005-03-16
EP1286695A1 (de) 2003-03-05
US20030162738A1 (en) 2003-08-28
US20070218073A1 (en) 2007-09-20
AU2001262345A1 (en) 2001-12-17

Similar Documents

Publication Publication Date Title
DE60109443D1 (de) Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält
DE60144145D1 (de) Subtilisin-variante
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
DK1255826T3 (da) Automatisering af proteindesign for proteinbiblioteker
ATE380822T1 (de) Funf-helix protein
AU2001291687A1 (en) Polyammonium-polysiloxane compounds, methods for the production and use thereof
PT1242121E (pt) Composicoes polipeptidicas com estabilidade melhorada
ATE384119T1 (de) Isoprenoidproduktion
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
NI200800193A (es) Anticuerpos humanos anti-il-23, composiciones, métodos y usos.
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
CY1106056T1 (el) Παραγωγα 2-αμινο-2-αλκυλ-5-επτενοϊκου και επτυνοϊκου οξεος χρησιμα σαν αναστολεις συνθασης νιτρικου οξειδιου
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
AU2001269575A1 (en) Nucleic acid sequences and proteins involved in cellular senescence
ATE321853T1 (de) Humanische pellino-polypeptide
WO1999004011A3 (en) Hiv-1 group o antigens and uses thereof
EP1279677A4 (de) Gd3 mimetische peptide(05.11.01)
DE60221805D1 (de) Peptide mit affinität zu gp120, und ihre verwendungen
ATE342511T1 (de) Methode zur in vivo identifizierung von intrazellularen epitopen
TW200505943A (en) Polypeptide
DE60113596D1 (de) Gasreformer zur Rückgewinnung von Wasserstoff
WO2005072766A3 (en) Peptides that bind to hsp90 proteins
DE50109166D1 (de) Verfahren zur verbesserung der transfektionseffizienz
Madine The stress timebomb

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee